CD28 and central nervous system cancer: A third-generation EGFRvIII CAR-T cell with a CD28 and a 4-1BB co-stimulatory domain was evaluated in a syngeneic, fully immune-competent mouse model after challenge with the murine glioma parental cell lines SMA560vII.